



**QUEEN'S
UNIVERSITY
BELFAST**

Novel combination of non-invasive morphological and solid-state characterisation of drug-loaded core-shell electrospun fibres

Kazsoki, A., Farkas, A., Balogh-Weiser, D., Mancuso, E., Sharma, P., Lamprou, D., & Zelkó, R. (2020). Novel combination of non-invasive morphological and solid-state characterisation of drug-loaded core-shell electrospun fibres. *International Journal of Pharmaceutics*, 587, Article 119706. Advance online publication.

Published in:

International Journal of Pharmaceutics

Document Version:

Peer reviewed version

Queen's University Belfast - Research Portal:

[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights

Copyright 2020 Elsevier.

This manuscript is distributed under a Creative Commons Attribution-NonCommercial-NoDerivs License

(<https://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.

General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Open Access

This research has been made openly available by Queen's academics and its Open Research team. We would love to hear how access to this research benefits you. – Share your feedback with us: <http://go.qub.ac.uk/oa-feedback>

1 **Novel combination of noninvasive morphological and solid-state characterization of**
2 **drug-loaded core-shell electrospun fibers**

3
4 Adrienn Kazsoki¹, Attila Farkas², Diána Balogh-Weiser^{2,3}, Elena Mancuso⁴, Preetam K.
5 Sharma⁴, Dimitrios A. Lamprou⁵, Romána Zelkó^{1*}

6
7 ¹University Pharmacy Department of Pharmacy Administration, Semmelweis University,
8 Hógyes Endre utca 7-9, H-1092 Budapest, Hungary

9 ²Department of Organic Chemistry and Technology, Budapest University of Technology and
10 Economics, Műegyetem rakpart 3, H-1111 Budapest, Hungary

11 ³Department of Physical Chemistry and Materials Science, Budapest University of
12 Technology and Economics, Műegyetem rakpart 3, H-1111 Budapest, Hungary

13 ⁴Nanotechnology and Integrated Bio-Engineering Centre (NIBEC), Ulster University,
14 Jordanstown campus, UK

15 ⁵School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, UK

16
17 **Corresponding author***: Romána Zelkó, zelko.romana@pharma.semmelweis-univ.hu

18
19 **ORCID:**

20 **Adrienn Kazsoki:** 0000-0002-0611-3124; **Attila Farkas:** 0000-0002-8877-2587; **Diána**
21 **Balogh-Weiser:** 0000-0002-9957-1203; **Elena Mancuso:** 0000-0003-1742-1656; **Preetam**
22 **K. Sharma:** 0000-0002-5694-8445; **Dimitrios A. Lamprou** 0000-0002-8740-1661; **Romána**
23 **Zelkó:** 0000-0002-5419-9137;


24
25 **Keywords**

26 coaxial electrospinning, core-shell electrospun fibers, drug delivery, Transmission electron
27 microscopy, Raman spectroscopy

28
29 **Chemical compounds studied in this article:**

30 levofloxacin (PubChem CID: 149096); naproxen-sodium (PubChem CID: 23681059);
31 polylactic acid (PubChem CID: 612); polyvinyl pyrrolidone (PubChem CID: 131751496);
32 polysorbate 80 (PubChem CID: 5284448); hydroxypropyl-beta-cyclodextrin (PubChem
33 CID:14049689); chloroform (PubChem CID: 6212); *N,N*-dimethylformamide (PubChem
34 CID: 6228); ethanol (PubChem CID: 702)

35 **Graphical abstract**



36
37

38 **Abstract**

39 Core-shell nanofibrous drug delivery systems have increasing attention in the last years due to
40 their potential to incorporate two or more active pharmaceutical ingredients (APIs)
41 individually into the desired layer (either core or sheath) and thus finely tune the release
42 profile of even incompatible drugs in one system. This study aimed to formulate, and solid-
43 state characterize levofloxacin-loaded polylactic acid (PLA) - naproxen-sodium-loaded
44 polyvinyl pyrrolidone (PVP) bicomponent core-shell fibrous sheets and examined the
45 electrospinnability of the precursor combinations. The selected drugs were of potential
46 therapeutic relevance in similar systems that intended for wound healing, but in the present
47 paper used as model drugs in order to understand the physicochemical properties of a drug
48 loaded system. In order to determine the best core-and shell solution combination, a full
49 factorial experimental design was used. The combination of various morphological (Scanning
50 Electron Microscopy, Transmission Electron Microscopy) and microstructural
51 characterization techniques (X-ray Photoelectron Spectroscopy and Raman spectroscopy) was
52 applied in order to noninvasively obtain information about the structure of the fibers and the
53 embedded drugs. The results indicated that core-shell fibers of different compositions were
54 successfully prepared with various structural homogeneities. The best core-shell structure was
55 obtained with 15% (w/w) shell concentration combined with 8 % (w/w) PLA solution
56 concentration. Besides the conventional core-shell structural verification methods, a Raman
57 spectroscopy method was implemented to reveal not only the core-shell structure of the
58 PLA/PVP nanofibers, but the form of the embedded drugs, as well. The Raman mapping of
59 the fibers confirm the above results and pointed out that as a results of the coaxial
60 electrospinning process amorphous solid dispersion was formed.

61

62

63 **1. Introduction**

64 Electrospinning is a well controllable, relatively simple and cost-effective technique for the
65 preparation of matrices with nano- and micrometer-sized fibers (Pelipenko et al., 2015; Smith
66 and Ma, 2004; Xue et al., 2019). The unique properties of the fibrous materials, such as the
67 high porosity with interconnected pore network and the increased surface area of the fibrous
68 sheets, together with the active pharmaceutical ingredients (APIs) can be embedded into the
69 polymeric matrix carrier in an amorphous state. These parameters could lead to an increased
70 dissolution and thus provide bioavailability of drugs with lower solubility (Huang et al.,
71 2003).

72 Due to nano- and microfibrillar materials unique structure, the vast material variety,
73 multifunction property and mass production, together with the formulation of nanofibrous
74 scaffolds loaded with different drugs or drug combinations have been widely used as drug
75 delivery systems for tissue engineering and wound bandage (Barnes et al., 2007; Haider et al.,
76 2018). This materials widespread biomedical application lies its similar features and
77 morphologies to the extracellular matrix, which is the non-cellular component presents within
78 all tissues and organs, plays a crucial role in the wound healing process (Liu et al., 2017).
79 Therefore, materials that can mimic their structure and can stimulate cell proliferation could
80 help the wound healing (Rieger et al., 2013). Zahra et al., reported that a core-shell structure
81 could provide a more controlled release of a model biocide with prolonged antibacterial
82 properties than single nanofibers. These nanofibrous mats have the potential to selectively
83 release antibacterial agents to prevent wound infections without delaying wound healing
84 (Abdali et al., 2019).

85 However, the diverse field of applications required adequate functionality-related
86 characteristics. In order to fulfil the increased quality and functionality requirement of the
87 fibrous scaffolds, one of the emerging improvements is the development of a multicomponent
88 core-shell fibrous structure, that can provide additional unique and essential properties that are
89 relevant for biomedical applications (Elahi et al., 2013). The core polymer/composite can
90 ensure features that are required for tissue regeneration. At the same time, the shell materials
91 could preserve the unstable APIs embedded into the core from the unfavourable
92 environmental effect, and can improve the hydrophilicity and the biocompatibility of the
93 fibrous samples (Elahi et al., 2013; Han and Steckl, 2019). Besides that, one of the significant
94 advantages of this core-shell nanostructures lies in the potential to tailor release properties of
95 the incorporated drug, which is readily available with the careful choice of the drug-polymer-

96 solvent (or solvent mixture) precursor system (Huang and Thomas, 2018; Jiang et al., 2005).
97 Basically, the core-shell fibrous structure can provide four directions to improve the polymer-
98 based nanofibrous drug delivery systems (Han and Steckl, 2019):

- 99 (1) Combining two/three or more polymer and polymer-composition in a single fiber, which
100 can provide the required biocompatibility and mechanical properties.
- 101 (2) With the drug incorporation into the core and covered by the shell, a sustained release of
102 the drug can be achieved.
- 103 (3) There is the ability to incorporate two or more APIs individually into the desired layer
104 (either core or sheath) and thus controlled release kinetics of the embedded drugs can be
105 achieved.
- 106 (4) Trigger release: external stimuli-responsive controlled release is also feasible (Han and
107 Steckl, 2019).

108 Although the bases of the production of core-shell type nanofibers are known in the literature,
109 the development of a new core-shell system is still challenging. Even so, several drug
110 combinations incorporated into the various polymer-based core-shell fibers; however, a core-
111 shell structure verification technique has not been studied widely yet. A few studies are
112 available, where the structure verification was investigated only with scanning electron
113 microscopy (SEM) measurements (Huang and Thomas, 2018; Khalf et al., 2015). But it
114 should be noted that, SEM can be a useful tool to verify the core-shell structure of the fibers,
115 if the core component can be selectively extracted (Wang et al., 2010).


116 The typical and conventional core-shell structure characterization technique is the
117 transmission electron microscopy (TEM), which is capable of detecting the materials with
118 different densities. That is primarily applicable where different core- and shell material were
119 used. However, it is also possible to make a core-shell fibrous sample using the same polymer
120 as core and sheath materials. Still, in this case, this method is less applicable, which is due to
121 the rather small difference in density caused by only the APIs (Alharbi et al., 2018; Chen et
122 al., 2010; Pakravan et al., 2012; Sun et al., 2003; Zhang et al., 2004).

123 Atomic force microscopy (AFM) has also used to justify the structure, which applicability lies
124 on the observation of the surface morphologies of single needle electrospun samples and the
125 coaxial electrospun scaffold and even on the mechanomanipulation of the force spectroscopy.
126 Still, for this measurement essential a sample of sparse surface coverage with least overlap
127 between the fibers and only those part of the sample can be examined, that is totally lying on
128 the disc (Chen et al., 2015; Kazsoki et al., 2018; Zander et al., 2011).

129 Another novel non-invasive technique is the Raman mapping, which can provide structural
 130 and quantitative information of the fibers by monitoring selective peaks of the polymers and
 131 the APIs (if their concentrations are big enough) – the technique is suitable for tracking the
 132 physical state of the embedded drugs (Farkas et al., 2015; Sfakis et al., 2017; Sharikova et al.,
 133 2020). However, due to its resolution limitation, it can be used effectively only in case of
 134 fibers with larger diameters (close or over micrometre size).

135 This study aimed to prepare levofloxacin-loaded poly(lactic acid) (PLA) - naproxen-sodium-
 136 loaded poly(vinylpyrrolidone) (PVP) bicomponent core-shell fibrous sheets and examine the
 137 electrospinnability of the precursor combinations. The selected APIs have a potential
 138 therapeutic relevance in wound healing, but in the present paper, these molecules have been
 139 used as model drugs in order to understand the physicochemical properties of a drug-loaded
 140 core-shell fiber based system. A full factorial experimental design (of two factors in three
 141 levels) was used to determine the best combination of the drug-loaded core (PLA)-and shell
 142 (PVP) viscous solutions for coaxial electrospinning. The combination of conventional (as
 143 TEM and XPS) and novel morphological and solid-state characterization methods (like
 144 Raman spectroscopy) was applied to simultaneously monitor the core-shell structure and the
 145 form of actives embedded to the core and shell polymers. The studies performed in order to
 146 investigate the best composition with excellent fiber structure characteristic for potential
 147 application in chronic wound healing (**Fig. 1**).

148



149

150

Fig. 1 Schematic representation of the steps and focus of the manuscript.

151

152 **2. Materials and methods**

153 **2.1. Materials**

154 Levofloxacin ((*S*)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-7*H*-
155 pyrido[1,2,3-*de*]-1,4-benzoxazine-6-carboxylic acid) >98%, $M=361.37 \text{ g mol}^{-1}$) and
156 naproxen-sodium ((*S*)-6-Methoxy- α -methyl-2-naphthaleneacetic acid sodium salt, >98%,
157 $M=252.24 \text{ g mol}^{-1}$) were obtained commercially from Sigma-Aldrich (Budapest, Hungary)
158 and were used as APIs. Polylactic acid (PLA, *GF45989881*, $M_w \sim 85000\text{-}160000 \text{ g mol}^{-1}$
159 nominal granule size of 3-5 mm, density 1.24 g cm^{-3}) was chosen as the bases of the core part
160 of the fibers, and poly(vinyl pyrrolidone) (PVP, Kollidon K90, average $M_w \sim 1500000 \text{ g mol}^{-1}$)
161 was chosen for shell polymer, and both of them were obtained from Sigma-Aldrich
162 (Budapest, Hungary). Hydroxypropyl-beta-cyclodextrin (average degree of substitution (*n*)
163 ~ 4.5 , $(1135.0 + n \cdot 58.1) \text{ g mol}^{-1}$) was purchased from Cyclolab Ltd. (Budapest, Hungary).
164 Polysorbate 80 was purchased from Molar Chemicals (Budapest, Hungary). Absolute ethanol
165 (Molar Chemicals, Budapest, Hungary) and distilled water were used to prepare shell
166 electrospinning precursor. As a solvent of the viscous solution of the core chloroform
167 (anhydrous containing amylenes as stabilizers grade, >99%, Sigma Aldrich, Budapest,
168 Hungary), and *N,N*-dimethylformamide (DMF, anhydrous grade 99,8%, Sigma Aldrich,
169 Budapest, Hungary) were used. The materials were used without further purification.

170

171 **2.2. Preparation of polymer precursors for electrospinning experiments**

172 In this study, PLA and PVP were the chosen polymers for the core and sheath components,
173 respectively.

174 Since the use of a precursor, solution has a significant impact on the success of the
175 electrospinning process and the prepared samples morphology, preliminary experiments were
176 done to determine the optimal composition of viscous polymer solutions for the shell and core
177 formation. Therefore, the concentrations of the polymer solutions, the applied solvent mixture
178 and other additives (the polysorbate 80) were determined.

179 For the shell solution water: ethanol 8:2 (m:m) and for the core solution chloroform: DMF 6:1
180 (m:m) solvent was used. The previous experimentation revealed that under 7% (w/w) PLA
181 concentration, the single needle electrospinning did not result in bead-free, continuous fibers.
182 Naproxen-sodium-loaded PVP solutions and levofloxacin-loaded PLA solutions were
183 prepared by using the appropriate amount of composition and solvent mixture under magnetic
184 stirring until a clear, viscous solution was obtained. Both of the core and sheath solutions

185 were contained 0.5 % (w/w) polysorbate 80. The sheath solutions were containing 2 % (w/w)
186 non-steroidal anti-inflammatory drug and 14 % (w/w) HP- β -CD. The levofloxacin
187 concentration of the core solution was adjusted to 0.5 % (w/w).

188 A full factorial design of experiment was used to optimize fiber composition. The two factors
189 were the core- and the shell polymer solution concentration and each of them was examined
190 in three-level. Only the polymer concentration differed between the appropriate solutions.
191 Based on the preliminary single-needle electrospinning experiments, the PLA concentration
192 (factor 1) was chosen for 7, 8, 9 % (w/w), while 14, 15, 16 % (w/w) PVP concentration
193 (factor 2) was examined (**Table 1**).

194 **Table 1** Design of experiments (DoE) by indicating the various electrospun samples

sample		factor 1		
		level -1	level 0	level +1
factor 2	level -1	CS_1	CS_2	CS_3
	level 0	CS_4	CS_5	CS_6
	level +1	CS_7	CS_8	CS_9

195

196 **2.3. Coaxial electrospinning**

197 Lab-scale coaxial electrospinning equipment (SpinSplit Ltd., Budapest, Hungary) was used
198 for the fiber preparations. The homogenous precursor solutions were placed into plastic
199 syringes (Luer lock syringe, Sigma Aldrich Ltd., Budapest, Hungary) that were connected to
200 the conventional- (22 gauge) or coaxial emitter (inner needle gauge 22 and outer needle gauge
201 18) by teflon tubing. Pump systems provided the continuous feeding rate, which was 0.08 μ l/s
202 and 0.2 μ l/s for core- and shell solution, respectively. The applied voltage was examined
203 between 10-25 kV and the emitter to collector distance was set between 10-20 cm. Finally, the
204 best fiber characteristic was achieved when 15 \pm 0.5 kV high voltage was applied, and the
205 emitter to collector distance was set to 20 cm.

206 The samples were collected on a grounded aluminum plate covered with aluminum foil.
207 During the electrospinning process, the Taylor cone formation and its stability were
208 monitored by the camera system of the equipment, which support to identify best process
209 parameters. The electrospinning experiments were performed in a well-controlled room at an
210 ambient temperature of 22 \pm 1 $^{\circ}$ C with a relative humidity of 50 \pm 5 %.

211

212 **2.4. Scanning electron microscopy (SEM)**

213 The samples were fixed by a conductive double-sided carbon adhesive tape and then coated
214 with a gold layer (JEOL JFC-1200 Fine Coater, JEOL Ltd., Tokyo, Japan). SEM images were

215 taken with a JEOL JSM-6380LA scanning electron microscope (JEOL Ltd., Tokyo, Japan).
216 The acceleration voltage and the working distance were 15 kV and 10 mm, respectively.

217

218 **2.5. Transmission Electron Microscope (TEM)**

219 The core-shell structure of the coaxially electrospun nanofibers were examined on a JEOL
220 JEM-2100F transmission electron microscope (TEM), operated at 200 kV. Samples for TEM
221 analysis were prepared by directly depositing the as-spun nanofibers on a carbon grid (Agar
222 Scientific) followed by fixing with a methanol drop. The TEM images were recorded using a
223 charge-coupled device (CCD) camera controlled via Gatan DigitalMicrograph[®] software.

224

225 **2.6. X-ray Photoelectron Spectroscopy (XPS)**

226 In order to determine the chemical composition of the samples' surface (<5-10 nm), XPS
227 measurements were carried out on a Kratos Axis Ultra instrument using Al K_{α1} X-ray source
228 ($h\nu = 1486.7$ eV). The core-shell fibers electrospun onto aluminum foil were used for the XPS
229 analysis. Wide energy survey scans (WESS) were performed for samples over the range of 0-
230 1205 eV binding energy and pass energy of 160 kV.

231 A survey scan spectrum was taken, and the surface elemental compositions relative to carbon
232 was calculated from the peak area with a correction for atomic sensitivity. The XPS spectra
233 were analyzed using CasaXPS software. The quantification peaks were fitted using mixed
234 Gaussian-Lorentzian (GL30) function after performing a Shirley background correction.

235

236 **2.7. Raman microscopy measurements**

237 The Raman spectroscopy measurements were carried out using LabRAM system (Horiba
238 Jobin-Yvon, Lyon, France) coupled with an Olympus BX-40 optical microscope (Olympus,
239 Hamburg, Germany) and with 532 nm Nd:YAG laser source (Sacher Lasertechnik, Marburg,
240 Germany). For optical imaging, objectives of 20x and 100x magnifications were used.

241 A monochromator and Charge-Coupled-Device (CCD) detector were used for dispersion and
242 detection of Raman photons, and during the measurements intensity filter (D=0.3) was
243 applied. The data collected and processed using the Labspec 5 software.

244 During the measurements of reference samples (active pharmaceutical ingredients, polymers,
245 cyclodextrin, and polysorbate), 20x objective was used. First, the spectra were collected over
246 a more comprehensive spectral range of 100-2000 cm⁻¹, with that aim to select later the final
247 measuring spectral range where most of the relevant signals of the fibrous samples can be
248 detected. Finally, the spectral range of 346-1790 cm⁻¹ was selected as the most suitable range

249 for data acquisition, and for this, a 1800 groove/mm optical grating was set to 1100 cm^{-1} . The
250 resolution was 5 cm^{-1} . In the case of some components, fluorescence interference with
251 different levels was observed, which was removed with baseline correction.

252 Remarkable differences were observed in the Raman activity between the individual
253 components. While in the case of the crystalline drugs, 2 s acquisition time was sufficient to
254 achieve ten thousand times intensities, while 8-30 s was required for the excipients to provide
255 an excellent signal to noise ratio. For the measurements of the fibrous sample, an objective of
256 100x was used.

257 As for the Raman analysis, single fibers were suitable; the different nanofibrous samples
258 (placebo-, and drug-loaded fibers) were electrospun for 3-4 s on a glass microscope slide
259 covered by aluminum foil. These samples were investigated without any further sample
260 preparation.

261 For the spatial distribution measurements, vertical fibers in the Y direction were chosen,
262 which were monitored by the systematically moving of the motorized stage along in line in
263 the X-direction. Each of the maps was collected with 0.1 μm step size. For the evaluation, the
264 spectra of the placebo and drug-loaded fibers prepared by single-needle electrospinning were
265 used.

266 The mapped spectra as well as the reference spectra corrected by fitting the linear baseline
267 through specified points; all the spectra normalized by area.

268

269

270 **3. Results and discussion**

271 **3.1 Morphological characterization**

272 The SEM was used to investigate the morphology of the prepared sample by coaxial-
273 electrospinning. SEM images of the electrospun samples showed that random orientated,
274 clearly fibrous structure without beads and film-like elements were achieved with submicron
275 fiber diameter sized (**Fig.2**). Remarkable differences could not be observed between the
276 densities of the fibers in case of the core-shell fibrous samples electrospun from different
277 precursor combinations.




Fig. 2 SEM images of coaxially electrospun samples


CS_1 (A), CS_2 (B), CS_3 (C), CS_4 (D), CS_5 (E), CS_6 (F), CS_7 (G), CS_8 (H) and
CS_9 (I)

3.2 Structural investigation

The verification of the core-shell structure of the electrospun samples investigated by TEM measurements. **Fig. 3** shows the TEM micrographs of the core-shell structure of the composite ultrafine fibers. It was found that for the samples coded CS_4, CS_5, CS_6 and CS_7 (as can be seen in **Fig. 3 D, E, F, G** respectively), the diameter of the core structure was uniform throughout the fiber, evidencing a sharp core-shell interface for all the samples analysed. According to previous studies, this implies that the core and shell materials have different electron transmission ability (Zhang et al., 2006). In addition, the form of sharp boundaries is associated with the fast processing characteristic of electrospinning, preventing the mixing between the core solutions with the shell solution (Chen et al., 2010; Sun et al., 2006). For the samples based on 14% of PVP as well as for the 16% PVP with a core concentration of 8 and 9% PLA, the core-shell structure resulted irregular, with an evident effect on the resulting fiber morphology (**Fig. 3 A, B, C, H, I**). This could be attributed to the

296 fact that the core fluid jet out of coaxial capillaries might be split into a number of sub-jets
297 during the electrospinning process (Xue et al., 2019).

298



299

300 **Fig. 3** TEM images of sample CS_1 (A), CS_2 (B), CS_3 (C), CS_4 (D), CS_5 (E), CS_6 (F),
301 CS_7 (G), CS_8 (H) and CS_9 (I) coaxially electrospun samples

302


303 3.3 Surface characterization of the fibrous samples

304 The elemental composition on the surface of the PVP/PLA core-shell electrospun nanofiber
305 characterized *via* XPS. In **Fig. 4** the WESS from all the core-shell samples are reported. As
306 expected, the coaxial electrospun meshes showed very similar spectra across the different
307 samples, characterized by four peaks corresponding to C1s (binding energy, 286 eV), N1s
308 (binding energy, 400 eV), O1s (binding energy, 532 eV) and Na1s (binding energy, 1072 eV).

309 This suggests the consistent composition of the shell in all the samples. Moreover, the XPS
310 data show no F and Cl signal on the PVP nanofiber surface. Since XPS elemental analysis can
311 detect at the uppermost $\sim 100 \text{ \AA}$ in-depth of an analyzed specimen (Sun et al., 2002). The
312 absence of F 1s and Cl 2p peaks on the XPS spectra of the nanofiber surfaces indicates the
313 following:

- 314 i) The shell thickness is at least beyond the ultimate detection depth of XPS (i.e., 5-
- 315 10 nm).
- 316 ii) A good interfacial stability exists between the inner and the outer solution.
- 317 iii) Is an effective manufacturing electrospinning process (Sun et al., 2002).

318



319

320 **Fig. 4** XPS survey scan spectra from the coaxially produced nanofiber samples: CS_1 (A),
321 CS_2 (B), CS_3 (C), CS_4 (D), CS_5 (E), CS_6 (F), CS_7 (G), CS_8 (H) and CS_9 (I)
322 in 0-1200 eV range

323


324 3.4 Raman mapping

325 Besides the desired structure verification, investigation of the physical state of the embedded-
326 drugs has a great impact on the drug delivery systems, because these affect the drug-release
327 and the short- and long-term stability of the final dosage form. Raman mapping is a useful

328 mean to answer these questions. Based on the TEM results, the best three compositions were
329 selected for further analysis of Raman spectroscopy, in which the effect of factor 1 can be
330 examined.

331 **Fig. 5** shows the Raman spectra of the active pharmaceutical ingredients, the placebo-and
332 drug-loaded samples. Although in the case of the fibrous samples, lower intensities could be
333 observed compared to the initial materials, the recorded spectra of the fibrous samples did not
334 differ remarkably, suggesting that the fiber formations less influenced the shape of the spectra
335 in the polymers.

336 It can be seen that there is a slight detectable difference between the spectra of crystalline
337 drugs and drug-loaded fibers. In the latter cases, fewer and weaker drug signals can be
338 observed. The broadening and merging of the spectra could be related to that the drugs
339 incorporated into the fibers in an amorphous state. In the case of the levofloxacin-loaded
340 fibrous sample, the most visible changing of the peak can see at 496, 518, 1555, 1621 and
341 1658 cm^{-1} , while the naproxen was contributed significantly more to the signals of the
342 polymeric carrier at 523, 750, 1389, 1486, 1581 and 1634 cm^{-1} .



343
344 **Fig. 5** Raman spectra of the model drugs, the placebo- and drug-loaded core- and shell
345 nanofibers prepared by single-needle electrospinning: levofloxacin (A), placebo core

346 nanofiber (B), levofloxacin-loaded core nanofiber (C), naproxen-Na (D), placebo shell
347 nanofiber (E), naproxen-Na-loaded shell nanofiber

348

349 A novel Raman mapping method was used to confirm the core-shell structure via the
350 monitoring of the selective polymer signals of the spectra. For the evaluation, the single core
351 and shell fiber reference spectra used and the spectral concentrations were calculated by
352 classical least squares (CLS) method by using the total range of mentioned spectral range of
353 346-1790 cm^{-1} . ~~Because of very low concentration of active ingredient in core polymer, thus~~
354 ~~even lower in CS samples, the signal of PLA at 1770 cm^{-1} mainly indicated the appearance of~~
355 ~~the core.~~

356 The Raman maps are showing the polymer component contribution in the fibers (**Fig. 6**). The
357 spectral concentration of the polymer components was normalized to 100%. The red line
358 shows the spectral concentration of the core polymer (the PLA), while the red line represents
359 the shell polymer (the PVP) concentration.

360 The signals from the edge of the fiber only came from the shell polymer, while the signals
361 from the centre part (of the 2D projection of the fiber) included contributions from both of the
362 used polymers, which is indicating the core-shell structure of the single coaxially electrospun
363 fiber. This is consistent with the other results of the structural investigation methods.




Fig. 6 Raman spectra from the core-shell fibrous samples
(A:CS_4, B: CS_5, C:CS_6)

364
365
366
367

368 5. Conclusion

369 Levofloxacin-loaded polylactic acid (PLA) - naproxen-sodium-loaded poly(vinylpyrrolidone)
370 (PVP) bicomponent core-shell fibrous sheets were formulated from precursors of different
371 concentrations according to a full factorial DoE to optimize the fiber composition. The SEM
372 measurements indicated that each of the nine examined core-shell precursor combinations
373 enabled the formation of clear fibrous mats. The set of the conventional fiber structure
374 characterization (e.g. TEM) indicated that core-shell fibers of different compositions were
375 successfully prepared with various structural homogeneities. The XPS spectra of the
376 nanofiber surfaces indicated that there is excellent interfacial stability between the inner and

377 outer polymer solution. The best sample was achieved with 15% (w/w) shell concentration
378 combined with 8 % (w/w) PLA solution concentration. Besides the conventional core-shell
379 structural verification methods, a Raman spectroscopy method was applied successfully to
380 reveal the core-shell structure of the PLA/PVP nanofibers, since the spatial distributions of
381 the polymers were found to be different in the sampling points; moreover, it was also pointed
382 out that amorphous solid dispersions were formed.

383 The core-shell fibrous materials have been successfully prepared in the literature using
384 numerous polymer combinations; however, there is no universal morphological
385 characterization method for structure verifications. With regard to the characterization of the
386 structure of the coaxially electrospun samples the properties of the used polymers are a major
387 consideration that should be considered when selecting characterization methods. A
388 combination of several methods may be required to obtain information about the structure.
389 Even with its limitation, the Raman mapping could be a universal method for the fiber
390 structure determination, all the more so as it can obtain information about the distribution of
391 the drug if the concentration of embedded drugs is large enough in the fibers. The latter could
392 be the subject of future research.

393

394 **6. Declarations**

395 **6.1. Funding**

396 This project was supported by ÚNKP-19-3-I New National Excellence Program of the
397 Ministry for Innovation and Technology.

398 **6.2. Conflict of interest disclosure**

399 The authors declare no conflict of interest.

400 **6.3. Availability of data and material**

401 Not applicable.

402 **6.4. Code availability**

403 Not applicable.

404 **6.5. Authors' Contributions**

405 *Adrienn Kazsoki* designed the experiments and accomplished the viscous solution preparation
406 and formulated the electrospun fibrous mats. Analyzed and evaluated the measurements and
407 wrote the manuscript. *Attila Farkas* performed and evaluated the Raman spectroscopy
408 measurements. *Elena Mancuso, Preetam K. Sharma, Dimitrios A. Lamprou* performed the
409 TEM and XPS measurements and analysis. *Diána Balogh-Weiser* performed the SEM
410 measurements. *Romána Zelkó* finalized the manuscript.

411 **References**

- 412 Abdali, Z., Logsetty, S., Liu, S., 2019. Bacteria-Responsive Single and Core–Shell
413 Nanofibrous Membranes Based on Polycaprolactone/Poly(ethylene succinate) for On-
414 Demand Release of Biocides. *ACS Omega* 4, 4063-4070.
415
- 416 Alharbi, H.F., Luqman, M., Khalil, K.A., Elnakady, Y.A., Abd-Elkader, O.H., Rady, A.M.,
417 Alharthi, N.H., Karim, M.R., 2018. Fabrication of core-shell structured nanofibers of poly
418 (lactic acid) and poly (vinyl alcohol) by coaxial electrospinning for tissue engineering.
419 *European Polymer Journal* 98, 483-491.
420
- 421 Barnes, C.P., Sell, S.A., Boland, E.D., Simpson, D.G., Bowlin, G.L., 2007. Nanofiber
422 technology: Designing the next generation of tissue engineering scaffolds. *Advanced Drug*
423 *Delivery Reviews* 59, 1413-1433.
424
- 425 Chen, R., Huang, C., Ke, Q., He, C., Wang, H., Mo, X., 2010. Preparation and
426 characterization of coaxial electrospun thermoplastic polyurethane/collagen compound
427 nanofibers for tissue engineering applications. *Colloids and Surfaces B: Biointerfaces* 79,
428 315-325.
429
- 430 Chen, Y., Qian, C., Miao, N., 2015. Atomic force microscopy indentation to determine
431 mechanical property for polystyrene–silica core–shell hybrid particles with controlled shell
432 thickness. *Thin Solid Films* 579, 57-63.
433
- 434 Elahi, M.F., Lu, W., Guopling, G., Khan, F., 2013. Core-shell Fibers for Biomedical
435 Applications- A Review. *Journal of Bioengineering & Biomedical Science*.
436
- 437 Farkas, A., Vajna, B., Sóti, P.L., Nagy, Z.K., Pataki, H., Van der Gucht, F., Marosi, G., 2015.
438 Comparison of multivariate linear regression methods in micro-Raman spectrometric
439 quantitative characterization. *Journal of Raman Spectroscopy* 46, 566-576.
440
- 441 Haider, A., Haider, S., Kang, I.-K., 2018. A comprehensive review summarizing the effect of
442 electrospinning parameters and potential applications of nanofibers in biomedical and
443 biotechnology. *Arabian Journal of Chemistry* 11, 1165-1188.
444
- 445 Han, D., Steckl, A.J., 2019. Coaxial Electrospinning Formation of Complex Polymer Fibers
446 and their Applications. *ChemPlusChem* 84, 1453-1497.
447
- 448 Huang, C., Thomas, N.L., 2018. Fabricating porous poly(lactic acid) fibres via
449 electrospinning. *European Polymer Journal* 99, 464-476.
450
- 451 Huang, Z.-M., Zhang, Y.Z., Kotaki, M., Ramakrishna, S., 2003. A review on polymer
452 nanofibers by electrospinning and their applications in nanocomposites. *Composites Science*
453 *and Technology* 63, 2223-2253.
454
- 455 Jiang, H., Hu, Y., Li, Y., Zhao, P., Zhu, K., Chen, W., 2005. A facile technique to prepare
456 biodegradable coaxial electrospun nanofibers for controlled release of bioactive agents.
457 *Journal of Controlled Release* 108, 237-243.
458
- 459 Kazsoki, A., Szabó, P., Domján, A., Balázs, A., Bozó, T., Kellermayer, M., Farkas, A.,
460 Balogh-Weiser, D., Pinke, B., Darcsi, A., Béni, S., Madarász, J., Szente, L., Zelkó, R., 2018.

461 Microstructural Distinction of Electrospun Nanofibrous Drug Delivery Systems Formulated
462 with Different Excipients. *Molecular Pharmaceutics* 15, 4214-4225.
463

464 Khalf, A., Singarapu, K., Madihally, S.V., 2015. Cellulose acetate core-shell structured
465 electrospun fiber: fabrication and characterization. *Cellulose* 22, 1389-1400.
466

467 Liu, M., Duan, X.-P., Li, Y.-M., Yang, D.-P., Long, Y.-Z., 2017. Electrospun nanofibers for
468 wound healing. *Materials Science and Engineering: C* 76, 1413-1423.
469

470 Pakravan, M., Heuzey, M.-C., Aji, A., 2012. Core-Shell Structured PEO-Chitosan
471 Nanofibers by Coaxial Electrospinning. *Biomacromolecules* 13, 412-421.
472

473 Pelipenko, J., Kocbek, P., Kristl, J., 2015. Critical attributes of nanofibers: Preparation, drug
474 loading, and tissue regeneration. *International Journal of Pharmaceutics* 484, 57-74.
475

476 Rieger, K.A., Birch, N.P., Schiffman, J.D., 2013. Designing electrospun nanofiber mats to
477 promote wound healing – a review. *Journal of Materials Chemistry B* 1, 4531-4541.
478

479 Sfakis, L., Sharikova, A., Tuschel, D., Costa, F.X., Larsen, M., Khmaladze, A., Castracane, J.,
480 2017. Core/shell nanofiber characterization by Raman scanning microscopy. *Biomed. Opt.*
481 *Express* 8, 1025-1035.
482

483 Sharikova, A., Foraida, Z.I., Sfakis, L., Peerzada, L., Larsen, M., Castracane, J., Khmaladze,
484 A., 2020. Characterization of nanofibers for tissue engineering: Chemical mapping by
485 Confocal Raman microscopy. *Spectrochimica Acta Part A: Molecular and Biomolecular*
486 *Spectroscopy* 227, 117670.
487

488 Smith, L.A., Ma, P.X., 2004. Nano-fibrous scaffolds for tissue engineering. *Colloids and*
489 *Surfaces B: Biointerfaces* 39, 125-131.
490

491 Sun, B., Duan, B., Yuan, X., 2006. Preparation of core/shell PVP/PLA ultrafine fibers by
492 coaxial electrospinning. *Journal of Applied Polymer Science* 102, 39-45.
493

494 Sun, Y., Yin, Y., Mayers, B.T., Herricks, T., Xia, Y., 2002. Uniform Silver Nanowires
495 Synthesis by Reducing AgNO₃ with Ethylene Glycol in the Presence of Seeds and Poly(Vinyl
496 Pyrrolidone). *Chemistry of Materials* 14, 4736-4745.
497

498 Sun, Z., Zussman, E., Yarin, A.L., Wendorff, J.H., Greiner, A., 2003. Compound Core-Shell
499 Polymer Nanofibers by Co-Electrospinning. *Advanced Materials* 15, 1929-1932.
500

501 Wang, C., Yan, K.-W., Lin, Y.-D., Hsieh, P.C.H., 2010. Biodegradable Core/Shell Fibers by
502 Coaxial Electrospinning: Processing, Fiber Characterization, and Its Application in Sustained
503 Drug Release. *Macromolecules* 43, 6389-6397.
504

505 Xue, J., Wu, T., Dai, Y., Xia, Y., 2019. Electrospinning and Electrospun Nanofibers:
506 Methods, Materials, and Applications. *Chemical Reviews* 119, 5298-5415.
507

508 Zander, N.E., Strawhecker, K.E., Orlicki, J.A., Rawlett, A.M., Beebe, T.P., 2011. Coaxial
509 Electrospun Poly(methyl methacrylate)-Polyacrylonitrile Nanofibers: Atomic Force

510 Microscopy and Compositional Characterization. *The Journal of Physical Chemistry B* 115,
511 12441-12447.
512
513 Zhang, Y., Huang, Z.-M., Xu, X., Lim, C.T., Ramakrishna, S., 2004. Preparation of
514 Core-Shell Structured PCL-r-Gelatin Bi-Component Nanofibers by Coaxial Electrospinning.
515 *Chemistry of Materials* 16, 3406-3409.
516
517 Zhang, Y.Z., Wang, X., Feng, Y., Li, J., Lim, C.T., Ramakrishna, S., 2006. Coaxial
518 Electrospinning of (Fluorescein Isothiocyanate-Conjugated Bovine Serum Albumin)-
519 Encapsulated Poly(ϵ -caprolactone) Nanofibers for Sustained Release. *Biomacromolecules* 7,
520 1049-1057.
521